DiaPort Closed-Loop Artificial Pancreas

Closed Loop Artificial Pancreas Using Intraperitoneal (IP) Insulin Via DiaPort®

The primary purpose of this pilot study is to test an artificial pancreas system which uses the intra-peritoneal (IP) route for insulin delivery in type 1 diabetic patients.

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes Mellitus
• Intervention / Treatment: Device: Artificial Pancreas for DiaPort system with Zone-MPC algorithm

Detailed Description

During this study, the investigators would like to evaluate the intra-peritoneal insulin delivery as a potential breakthrough method for delivering insulin within the artificial pancreas system.

The intent is to exploit the rapid action achieved by IP insulin to compensate for meals and for management of the basal insulin needs. Patients will come for two closed-loop admissions of 24 hours. The first closed-loop will be performed using subcutaneous route, whereas the second one will be performed using the intra-peritoneale route.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34000
    • Montpellier University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient must be aged between 18 (inclusive) and 65 years old
• Patient must have been clinically diagnosed with Type 1 diabetes mellitus for at least one year
• Patient must have been identified as presenting an indication for the DiaPort® system, i.e. showing poor glucose control under Sc insulin delivery as shown by a sustained HbA1C level > 8% and/or high blood glucose variability including recurrent hypoglycemic events. Patient will be eligible for the study because he/she will have a DiaPort implanted.
• Patient must demonstrate proper mental status and cognition for the study
• Patient must be affiliated or beneficiary of a social medical insurance
• Patient has signed informed consent form prior to study entry

Exclusion Criteria:

• Unwilling to perform repeated glucose checks, consume standardized meals, and/or take insulin as instructed
• Evidence of cardiovascular event during the previous 6 months, non stabilized retinopathy, or clinically significant screening laboratory abnormalities
• Pregnancy, breast feeding, or intention of becoming pregnant
• Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions.
• Patient is actively enrolled in another clinical trial or was part of study within 30 days or whose annual study income is over 4 500€
• Persons deprived of freedom, adults protected by law or vulnerable persons

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Type 1 diabetic population; The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).	Device: Artificial Pancreas for DiaPort system with Zone-MPC algorithm; Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl)	Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl): in the basal or late postprandial period; in the early postprandial period (first 4 hours). All analyses will be done by using the YSI blood glucose measurements unless otherwise noted.	in the post prandial period (8 first hours after meal) during the in-clinic closed-loop 24-hour study period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean and standard deviation blood glucose	All analyses will include a comparison of the results in the Intraperitoneal versus Subcutaneous study days.	For the early postprandial period (first 4 hours after meal) and for the non-postprandial periods (from 8 hours after meal until next meal)
Percentage of time spent in hypoglycemia with blood glucose <3.3mmol/l (60 mg/dl)	All analyses will include a comparison of the results in the Intraperitoneal versus Subcutaneous study days.	during the 2 hospitalisations period when loop is closed (for a total of 24 hours)
Percentage of time spent in hyperglycemia	Percentage of time spent in hyperglycemia with blood glucose >10 mmol/l (180 mg/dl) in the early postprandial period; and Percentage of time spent in hyperglycemia>8mmol/l (144 mg/dl) in the basal or late postprandial period All analyses will include a comparison of the results in the Intraperitoneal versus Subcutaneous study days	in the early postprandial period (first 4 hours after meal) and in the basal or late postprandial period (from 8 hours after meal until next meal)

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: Eric ER RENARD, MD, PU-PH, Montpellier University Hospital

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (ACTUAL): March 1, 2013
• Study Completion (ACTUAL): March 1, 2013

Study Registration Dates

• First Submitted: February 28, 2012
• First Submitted That Met QC Criteria: March 14, 2012
• First Posted (ESTIMATE): March 15, 2012

Study Record Updates

• Last Update Posted (ACTUAL): October 20, 2021
• Last Update Submitted That Met QC Criteria: October 18, 2021
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: type 1 diabetes,; diaport,; artificial pancreas,; zone mpc algorithm,; ap system,; intraperitoneal insulin
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Gastrointestinal Agents; Pancrelipase
• Other Study ID Numbers: 8829; ID-RCB : 2011-A001212-39 (OTHER: Afssaps)